These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 1674363

  • 1. Addition of misoprostol to ranitidine in non-responders to H2-blockers and pirenzepine.
    Walker S, Sarem-Aslani A, Treiber G, Klotz U, Bode JC.
    Neth J Med; 1991 Feb; 38(1-2):18-23. PubMed ID: 1674363
    [Abstract] [Full Text] [Related]

  • 2. Combined effect of pirenzepine and ranitidine on the nocturnal intragastric pH in non-responders to ranitidine.
    Walker S, Klotz U, Bode JC.
    Z Gastroenterol; 1990 Aug; 28(8):379-82. PubMed ID: 2275257
    [Abstract] [Full Text] [Related]

  • 3. Do anticholinergics interact with histamine H2 receptor antagonists on night intragastric acidity in active duodenal ulcer patients?
    Fiorucci S, Clausi GG, Farinelli M, Santucci L, Farroni F, Pelli MA, Morelli A.
    Am J Gastroenterol; 1988 Dec; 83(12):1371-5. PubMed ID: 2904218
    [Abstract] [Full Text] [Related]

  • 4. [The effects of nizatidine and misoprostol on peptic activity and gastric mucus].
    Grassi SA, Vianello F, Germanà B, Dal Santo P, Faggian D, Battaglia G, Plebani M, Di Mario F, Naccarato R.
    Medicina (Firenze); 1990 Dec; 10(1):29-31. PubMed ID: 1974318
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological management of patients with peptic ulcer disease: prospects for the late 1980's.
    Thomson AB, Mahachai V.
    Clin Invest Med; 1987 May; 10(3):152-70. PubMed ID: 2887321
    [Abstract] [Full Text] [Related]

  • 6. Frequent non-response to histamine H2-receptor antagonists in cirrhotics.
    Walker S, Krishna DR, Klotz U, Bode JC.
    Gut; 1989 Aug; 30(8):1105-9. PubMed ID: 2570008
    [Abstract] [Full Text] [Related]

  • 7. [Experience of treatment of patients with gastropathy induced by non-steroid anti-inflammatory drugs].
    Vakhrushev IaM, Loshchakova OIu.
    Eksp Klin Gastroenterol; 2007 Aug; (1):60-3, 71. PubMed ID: 17547116
    [Abstract] [Full Text] [Related]

  • 8. [Drug therapy of peptic ulcer. What is coming up?].
    Müller P, Dammann HG, Simon B, Kommerell B.
    Leber Magen Darm; 1987 Feb; 17(1):50-4. PubMed ID: 3104707
    [Abstract] [Full Text] [Related]

  • 9. [The endoscopic assessment of the effect of ranitidine and pirenzepine on the manifestations of the gastropathy induced by nonsteroidal anti-inflammatory preparations].
    Karateev AE, Murav'ev IuV, Nasonova VA.
    Ter Arkh; 1997 Feb; 69(5):67-9. PubMed ID: 9235663
    [Abstract] [Full Text] [Related]

  • 10. [Drugs used in the therapy of peptic ulcer with special reference to H2 receptor blockaders].
    De Natale G, De Natale F, Marino A.
    Clin Ter; 1989 Apr 15; 129(1):3-16. PubMed ID: 2567647
    [Abstract] [Full Text] [Related]

  • 11. Anti-ulcer drugs in antisecretory doses for "cytoprotection" in arthritic patients?
    Londong W.
    Klin Wochenschr; 1986 Apr 15; 64 Suppl 7():32-4. PubMed ID: 2882050
    [Abstract] [Full Text] [Related]

  • 12. Controlling gastric pH: the impact of newer agents on the critically ill patient.
    Earnest DL.
    DICP; 1990 Nov 15; 24(11 Suppl):S31-4. PubMed ID: 1980181
    [Abstract] [Full Text] [Related]

  • 13. The therapeutic efficacy of misoprostol in peptic ulcer disease.
    Watkinson G, Hopkins A, Akbar FA.
    Postgrad Med J; 1988 Nov 15; 64 Suppl 1():60-77. PubMed ID: 3138682
    [Abstract] [Full Text] [Related]

  • 14. Prevention of NSAID-induced GI mucosal injury.
    Gerritz S, Newton WP.
    J Fam Pract; 1997 Feb 15; 44(2):130-1. PubMed ID: 9040509
    [No Abstract] [Full Text] [Related]

  • 15. Acid secretion and acid suppression in pathogenesis and healing of peptic ulcer disease.
    Thomson AB.
    Hepatogastroenterology; 1990 Jul 15; 37 Suppl 1():18-28. PubMed ID: 1976583
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evaluation of antisecretory activity of misoprostol in duodenal ulcer patients using long-term intragastric pH monitoring.
    Savarino V, Scalabrini P, Mela GS, di Timoteo E, Percario G, Magnolia MR, Celle G.
    Dig Dis Sci; 1988 Mar 15; 33(3):293-7. PubMed ID: 3125025
    [Abstract] [Full Text] [Related]

  • 19. Current concepts in clinical therapeutics: peptic ulcer disease.
    Siepler JK, Mahakian K, Trudeau WT.
    Clin Pharm; 1986 Feb 15; 5(2):128-42. PubMed ID: 2869852
    [Abstract] [Full Text] [Related]

  • 20. [The use of misoprostol in prevention of gastric disease from nonsteroidal anti-inflammatory drugs in oral-maxillofacial surgery].
    Bocca M, Giordano M, Del Pizzo M, Nelken A, Ghiggia M, Pomatto E.
    Minerva Ortognatod; 1990 Feb 15; 8(2):139-41. PubMed ID: 2126183
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.